Celestia S. Higano, MD | Authors

MEDI THRIFT PHARMACY

Articles

Targeting the Androgen Receptor Signaling Axis to Reduce Testosterone Levels in Prostate Cancer: How Low Should We Go?

August 15, 2014

It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.